

Performance in Delivering Clinical Trial Research Q1 2021 - 2022  
 Time to Target (Commercial Contracts)  
 Studies that have Closed to Recruitment in the Previous 12 months

Research Ethics Number	IRAS number	Name of Trial	Target Number of Patients Agreed?	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Target Date to Recruit Patients Agreed?	Date Agreed to Recruit Target No of Patients	Total Recruited by Agreed Target Date	Recruitment end date	Total Number of Study Participants Recruited	Trial Status	Target met	Comments
20/NW/0399	288793	A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom.	Number Agreed	330	330	Date Agreed	02/11/2020	377	30/11/2020	463	Recruitment Finished	Yes	